Get the Stockscreener App
4.24
7.07%
0.28
After Hours:
29.72
25.48
+600.94%
Relmada Therapeutics Inc stock is traded at $4.24, with a volume of 637.18K.
It is up +7.07% in the last 24 hours and up +68.92% over the past month.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
See More
Previous Close:
$3.96
Open:
$4.03
24h Volume:
637.18K
Relative Volume:
0.64
Market Cap:
$310.93M
Revenue:
-
Net Income/Loss:
$-98.79M
P/E Ratio:
-1.2966
EPS:
-3.27
Net Cash Flow:
$-51.66M
1W Performance:
-5.99%
1M Performance:
+68.92%
6M Performance:
+417.07%
1Y Performance:
+842.22%
1-Day Range:
$3.99
$4.31
1-Week Range:
$3.70
$4.50
52-Week Range:
$0.2404
$5.12
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Name
Relmada Therapeutics Inc
Sector
Industry
Phone
646 876 3459
Address
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
3.50 | 4.01B | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.2215 | 480.44M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
20.09 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
4.67 | 220.48M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
0.90 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-05-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Jun-05-24 | Downgrade | Goldman | Neutral → Sell |
| Oct-14-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-14-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-14-22 | Downgrade | Truist | Buy → Hold |
| Oct-13-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-18-21 | Initiated | Mizuho | Buy |
| May-20-21 | Resumed | Goldman | Buy |
| Oct-28-20 | Downgrade | Goldman | Buy → Neutral |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-04-20 | Initiated | SunTrust | Buy |
| Apr-21-20 | Initiated | Goldman | Buy |
| Jan-27-20 | Initiated | Jefferies | Buy |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-16-19 | Initiated | Guggenheim | Buy |
View All
Relmada Therapeutics Inc Stock (RLMD) Latest News
Can Relmada Therapeutics Inc. stock hit analyst price targetsM&A Rumor & Technical Pattern Based Signals - Newser
Will Relmada Therapeutics Inc. (4E2) stock outperform value peersJuly 2025 Chart Watch & Fast Entry High Yield Stock Tips - Newser
Will Relmada Therapeutics Inc. stock deliver strong dividend growthGap Down & Risk Adjusted Buy and Sell Alerts - Newser
Relmada Therapeutics’ Earnings Call Highlights Clinical and Financial Success - MSN
Relmada’s bladder cancer therapy shows 92% complete response rate By Investing.com - Investing.com Nigeria
Relmada Therapeutics Advances NDV-01 for Non-Muscle Invasive Bladder Cancer with Positive Phase 2 Follow-Up Data - Quiver Quantitative
Relmada Therapeutics (RLMD) reports 9-month 92% CR for NDV-01 in NMIBC, eyes Phase 3 - Stock Titan
Why Relmada Therapeutics Inc. (4E2) stock stays resilientRecession Risk & Trade Opportunity Analysis - Newser
Relmada Therapeutics (RLMD) Stock Analysis Report | Financials & Insights - Benzinga
What risks investors should watch in Relmada Therapeutics Inc. stockTrade Ideas & Fast Moving Trade Plans - Newser
How supply chain issues affect Relmada Therapeutics Inc. stockQuarterly Earnings Report & Long-Term Growth Plans - moha.gov.vn
Relmada Therapeutics Inc. (US75955J4022.SG) Balance Sheet - Yahoo! Finance Canada
Relmada Therapeutics Announces $100 Million Underwritten Offering - Global Legal Chronicle
Relmada Therapeutics Inc 4E2 Stock Analysis and ForecastVolume Analysis Techniques & Rapid Portfolio Trading - earlytimes.in
Pullback Watch: Is Relmada Therapeutics Inc. stock supported by innovation pipelineWeekly Trading Summary & Fast Momentum Entry Tips - moha.gov.vn
Is Relmada Therapeutics Inc. stock supported by strong cash flows - BỘ NỘI VỤ
Relmada Therapeutics, Inc.Common Stock (NQ: RLMD - Markets Financial Content
Views of Wall Street’s Leading Experts on Relmada Therapeutics Inc - Setenews
Relmada Therapeutics Inc. (RLMD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Relmada cut to neutral by Mizuho on Phase 3 study failure - MSN
Relmada Therapeutics, Inc. (RLMD) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
How risky is Relmada Therapeutics Inc. stock now2025 Key Lessons & Growth Focused Entry Reports - newser.com
How Relmada Therapeutics Inc. (4E2) stock trades in high volatilityEarnings Overview Report & Risk Controlled Daily Trade Plans - newser.com
This Stock Is Up 704% in 2025 But Has No Products to Its Name - inkl
Will Relmada Therapeutics Inc. stock sustain high P E ratiosCEO Change & Consistent Growth Equity Picks - newser.com
Is Relmada Therapeutics Inc. showing signs of accumulationQuarterly Portfolio Report & AI Enhanced Trade Execution Alerts - newser.com
Mizuho upgrades Relmada Therapeutics stock to Outperform on NDV-01 potential - Investing.com Nigeria
Smart tools for monitoring Relmada Therapeutics Inc.’s price actionWeekly Profit Analysis & Free Daily Entry Point Trade Alerts - newser.com
Mizuho Upgrades Relmada Therapeutics (RLMD) - Nasdaq
Will Relmada Therapeutics Inc. (4E2) stock outperform small cap peers - newser.com
What valuation ratios show for Relmada Therapeutics Inc. (4E2) stock - newser.com
Mizuho Upgrades RLMD to 'Outperform', Raises Price Target | RLMD Stock News - GuruFocus
Relmada Therapeutics (RLMD) Receives Upgrade with Significant Up - GuruFocus
Relmada Therapeutics upgraded by Mizuho with a new price target - Quantisnow
Mizuho Upgrades Relmada Therapeutics to Outperform From Neutral - MarketScreener
Is Relmada Therapeutics Inc. stock ready for a breakoutOptions Play & Community Driven Trade Alerts - newser.com
Mizuho Upgrades Relmada Therapeutics Inc (RLMD) to Outperform - StreetInsider
Relmada Therapeutics Inc Stock (RLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):